Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus exenatide ER once weekly in adults with type 2 diabetes on oral antidiabetic drugs
NL-OMON40243Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide once weekly with Exenatide extended-release once weekly (2 arms). Primary endpoint: Change in HbA1c from baseline to week 56. Started Jan 2014; status: active, not recruiting.
02
Drugs
semaglutideexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40243.